Insurers Off The Hook In BASF Synthroid Spat
An appeals court has done an about-face in an insurance-coverage action related to the marketing of synthetic thyroid drug Synthroid, ruling that a group of primary-insurance providers were not obligated to...To view the full article, register now.
Already a subscriber? Click here to view full article